

HBV 101:

FDA Approved Medications for Prevention and Treatment of Hepatitis B Virus

Laboratory Assesment	Dose	Common adverse effects	Laboratory Assesment
<p>interferon alfa-2b <i>Intron A</i> 3, 5, 10, 18, 25, 50 million IU</p> <p>Or</p> <p>peginterferon alfa-2a <i>Pegasys</i> 180 mcg/mL</p>	<p>HBeAg-positive patients: 5-6 million units SQ once-daily OR 9-10 million units SQ three times weekly x 4-6months</p> <p>HBeAg-negative patients: 5-6 million units SQ three times weekly x 12 months</p> <p>Peginterferon: 180 mcg SQ once weekly x 48 weeks</p>	<p>Anemia, granulocytopenia, throm- bocytopenia, psychiatric distur- bances (depression, suicide, psychosis), CNS effects such as seizures, ataxia, confusion, cardiac arrythmias, cardiomyopathy, my- ocardial infarction, hypotension, thy- roid disturbances, renal failure, dermatologic disturbances, injection site reactions</p>	<p>Should not be used in patients with severe depression or unstable psy- chiatric disorders, uncontrolled thy- roid disease or diabetes, in patients with ANC < 1.5 or platelets < 75 or in pregnant patients</p> <p>Monitor CBC, platelets, liver func- tion tests, TSH, blood glucose, renal function every 4 weeks</p>
<p>lamivudine <i>EpiVir-HBV</i> 100mg tablets</p>	<p>HBV monoinfected: 100mg orally once-daily</p> <p>HBV/HIV co-infected: 300mg orally once-daily, in combination with other agents to make a HAART regimen</p>	<p>Headache, fatigue, nausea, myopa- thy/myalgia, lactic acidosis, HBV flare upon abrupt discontinuation</p>	<p>Dose adjust in renal insufficiency</p>
<p>adefovir <i>Hepsera</i> 10mg tablets</p>	<p>10mg orally once-daily</p>	<p>Weakness, headache, nausea, ab- dominal pain, hematuria, renal dys- function, HBV flare upon abrupt discontinuation.</p>	<p>Dose adjust in renal insufficiency</p>
<p>entecavir <i>Baraclude</i> 0.5 and 1mg tablets</p>	<p>Treatment naive: 0.5mg orally once-daily</p> <p>Lamivudine experienced: 1mg orally once-daily</p>	<p>Headache, fatigue, hyperglycemia, elevated lipase and amylase, hema- turia, lactic acidosis, HBV flare upon abrupt discontinuation.</p>	<p>Dose adjust in renal insufficiency</p>
<p>telbivudine <i>Tyzeka</i> 600mg tablets</p>	<p>600mg orally once-daily</p>	<p>Fatigue, malaise, headache, ab- dominal pain, increased CPK, dizzi- ness, lactic acidosis, myopathy, HBV flare upon abrupt discontinua- tion.</p>	<p>Dose adjust in renal impairment. Consider baseline and follow up CPK.</p>